Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation

IUBMB Life

Volumn 64, Issue 2, 2012, Pages 157-161

  Hine, David ^a   MacKness, Bharti ^b   MacKness, Mike ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b C/l'Argelagar ^*  (Spain)

Author keywords

apo A1; HDL; LCAT; oxidation; paraoxonase 1

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDASE; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANTIOXIDANT ACTIVITY; ARTICLE; OXIDATION;

APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ESTERIFICATION; HUMANS; KINETICS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84855869657     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.588     Document Type: Article

References (21)

1. Lusis, A. J., (2000) Atherosclerosis. Nature 407, 233-241.
2. Ross, R., (1993) The pathogenesis of atherosclerosis: a perspective for the 1990′s. Nature 362, 801-809.
3. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and, Witztum, J. L., (1989) Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320, 915-924. (Pubitemid 19101597)
4. Mackness, B., and, Mackness, M., (2009) HDL-why all the fuss? Ann. Clin. Biochem. 46, 5-7.
5. Duverger, N., Kruth, H., Emmanuel, F., Caillaud, J.-M., Viglietta, C., Castro, G., Tailleux, A., Fiever, C., Fruchart, J.-C., Houdebine, L. M., and, Denèfle, P., (1996) Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation 94, 713-717. (Pubitemid 26289227)
6. Tangirala, R. K., Tsukamoto, K., Chun, S. H., Usher, D., Puré, E., and, Radar, D. J., (1999) Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein AI in mice. Circulation 100, 1816-1822. (Pubitemid 29498389)
7. Mertens, A., Verhamme, P., Bielicki, J. K., Phillips, M. C., Quarck, R., Verreth, W., Stengel, D., Ninio, E., Navab, M., Mackness, B., Mackness, M., and, Holvoet, P., (2003) Increased low density lipoprotein oxidation and impaired high density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice. LCAT gene transfer decreases atherosclerosis. Circulation 107, 1640-1646. (Pubitemid 36397333)
8. Mackness, B., Quarck, R., Verreth, W., Mackness, M., and, Holvoet, P., (2006) Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26, 1545-1550. (Pubitemid 44288981)
9. Shih, D. M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., and, Lusis, A. J., (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287. (Pubitemid 28335041)
10. Arrol, S., Mackness, M. I., and, Durrington, P. N., (1996) High-density lipoprotein associated enzymes and the prevention of low-density lipoprotein oxidation. Eur. J. Lab. Med. 4, 33-38. (Pubitemid 27067961)
11. Liu, Y., Mackness, B., and, Mackness, M., (2008) Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. Free Rad. Biol. Med. 45, 743-748.
12. Gan, K. N., Smolen, A., Eckerson, H. W., and, La Du, B. N., (1991) Purification of human serum paraoxonase/arylesterase. Drug Metab. Disp. 19, 100-106.
13. Piran, U., and, Morin, R., (1979) A rapid radioassay procedure for plasma lecithin:cholesterol acyltransferase. J. Lipid Res. 20, 1040-1043. (Pubitemid 10157719)
14. Mackness, M. I., and, Durrington, P. N., (1992) Lipoprotein separation and analysis for clinical studies. In Lipoprotein Analysis: A Practical Approach. (, Converse, C. A., and, Skinner, E. R., eds.). pp. 1-42, IRL Press, Oxford.
15. Rumsey, S., Galeano, N., Arad, Y., and, Deckelbaum, R. J., (1996) Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J. Lipid Res. 37, 2266-2267.
16. Matz, C. E., and, Jonas, A., (1982) Micellar complexes of human apolipoprotein AI with phosphatidylcholine and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257, 4535-4540.
17. Mackness, M. I., Abbott, C. A., Arrol, S., and, Durrington P. N., (1993) The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294, 829-835.
18. Mastorikou, M., Mackness, B., Liu, Y., and, Mackness, M., (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of HDL to metabolise membrane lipid hydroperoxides. Diabetic Med. 25, 1049-1055.
19. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C. L., Newton, R. S., and, La Du, B. N., (1999) Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad. Biol. Med. 26, 892-904. (Pubitemid 29198362)
20. Bielicki, J., and, Forte, T., (1999) Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J. Lipid Res. 40, 948-954. (Pubitemid 29220536)
21. Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., (2007) Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J. Clin. Invest. 117, 746-756. (Pubitemid 46348533)